OTLK · XBRL financial data
Outlook Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (OTLK's year ends in late September)
| In thousands of dollars | Sep 30, 2020 | Nov 30, 2021 | Sep 30, 2022 | Sep 30, 2023 | Sep 30, 2024 | Sep 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | — | — | — | — | — | 1,414 |
| Cost of goods and services sold | — | — | — | — | — | 1,356 |
| Gross profit | — | — | — | — | — | 57 |
| Research and development | 26,342 | — | 42,331 | 26,453 | 41,763 | 27,181 |
| Selling, general and administrative | — | — | — | — | 29,940 | 39,938 |
| General and administrative | 9,971 | — | 20,740 | 26,673 | 29,940 | — |
| Total operating expenses | 36,841 | — | — | — | — | — |
| Operating income (loss) | (36,841) | — | (63,071) | (53,126) | (71,703) | (67,062) |
| Interest income | — | — | — | 971 | 906 | 90 |
| Interest expense | 1,756 | — | — | 2,531 | 3,157 | — |
| Income tax expense (benefit) | (3,272) | — | 3 | 3 | 3 | (1,552) |
| Net income (loss) | (35,239) | — | (66,052) | (58,983) | (75,367) | (62,425) |
| Earnings per share, basic‡ USD per share | (13.40) | — | (6.20) | (4.80) | (4.06) | (1.79) |
| Earnings per share, diluted‡ USD per share | (13.40) | — | (6.20) | (4.80) | (4.06) | (1.79) |
| Weighted average shares, basic‡ thousands of shares | 3,628 | — | 10,604 | 12,509 | 18,549 | 34,796 |
| Weighted average shares, diluted‡ thousands of shares | 3,628 | — | 10,604 | 12,509 | 18,549 | 34,796 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (March 2024); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal years (OTLK's year ends in late September)
| In thousands of dollars | Sep 30, 2020 | Nov 30, 2021 | Sep 30, 2022 | Sep 30, 2023 | Sep 30, 2024 | Sep 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 12,536 | — | 17,397 | 23,392 | 14,928 | 8,083 |
| Accounts receivable | — | — | — | — | — | 1,491 |
| Inventory | — | — | — | — | — | 3,338 |
| Prepaid and other current assets | 5,408 | — | 10,124 | 7,587 | 12,488 | 4,477 |
| Total current assets | 17,944 | — | 27,520 | 30,979 | 27,416 | 17,389 |
| Property and equipment, net | 327 | — | — | — | — | — |
| Right-of-use asset | 167 | — | 70 | 26 | 275 | 226 |
| Total assets | 19,733 | — | 28,528 | 32,301 | 28,823 | 18,584 |
| Accounts payable | 2,395 | — | 3,491 | 6,575 | 7,969 | 10,192 |
| Accrued liabilities | 7,757 | — | 3,428 | 2,746 | 3,237 | 5,314 |
| Total current liabilities | 15,889 | — | 19,730 | 46,732 | 42,554 | 45,815 |
| Lease liability, non-current | — | — | — | — | 247 | 189 |
| Total liabilities | 16,906 | — | 19,791 | 46,738 | 101,900 | 50,772 |
| Accumulated deficit | (289,720) | — | (408,936) | (467,918) | (543,285) | (605,710) |
| Total stockholders' equity | 2,826 | — | 8,737 | (14,438) | (73,077) | (32,188) |
| Total liabilities and equity | 19,733 | — | 28,528 | 32,301 | 28,823 | 18,584 |
| Common shares outstanding (cover page)‡ thousands of shares | 6,359 | 11,213 | 11,410 | 13,013 | 24,906 | 64,114 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (March 2024); filings made before it reported them unadjusted.
Cash flows
CSVFiscal years (OTLK's year ends in late September)
| In thousands of dollars | Sep 30, 2020 | Nov 30, 2021 | Sep 30, 2022 | Sep 30, 2023 | Sep 30, 2024 | Sep 30, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (35,239) | — | (66,052) | (58,983) | (75,367) | (62,425) |
| Stock-based compensation | 2,807 | — | 7,711 | 5,547 | 5,385 | 8,898 |
| Depreciation and amortization | 219 | — | — | — | — | — |
| Net cash from operating activities | (31,790) | — | (56,675) | (42,973) | (68,794) | (51,829) |
| Net cash from investing activities | (900) | — | — | — | — | — |
| Proceeds from issuing common stock | 35,431 | — | 62,307 | 30,024 | 60,334 | 25,396 |
| Net cash from financing activities | 37,211 | — | 59,594 | 48,969 | 60,329 | 44,985 |
| Net change in cash | 4,520 | — | 2,919 | 5,995 | (8,464) | (6,844) |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Outlook Therapeutics | 11,242 | not reported | (21,011)* | 243.4M | 0.5 quarters | 10-QJun 30, 2026 |
| OnKure Therapeutics | 166,502 | not reported | (10,354)* | 40.5M | 17.0 quarters | 10-QJun 30, 2026 |
| Palatin Technologies | 7,492 | 301* | (2,690)* | 1.8M | 2.8 quarters | 10-KJun 30, 2026 |
| Scynexis | 10,487 | 235 | (14,885)* | 9.9M | 3.6 quarters | 10-QJun 30, 2026 |
| Champions Oncology | 4,358 | 15,232 | (492) | 13.9M | 8.0 quarters | 10-QJul 31, 2026 |
| Rockwell Medical | 10,519 | not reported | 2,080* | 4.0M | — | 10-QJun 30, 2026 |
| Pulmatrix | 2,168 | not reported | (1,106)* | 3.7M | 2.0 quarters | 10-QJun 30, 2026 |
| Curis | 5,073 | 0 | (9,646)* | 2.1M | 0.5 quarters | 10-QJun 30, 2026 |
| Cumberland Pharmaceuticals | 3,862 | 166 | 169* | 15.0M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.